Shire Settles Patent Battle With Par Unit Over ADHD Drug

Law360, New York (September 6, 2012, 7:10 PM EDT) -- A Shire PLC subsidiary settled patent infringement claims Thursday against a Par Pharmaceutical Co. unit and TWi Pharmaceuticals Inc. over their plans to market a generic version of Shire's attention deficit hyperactivity drug, in a deal giving the generics makers licensing rights in 2016.

Shire LLC will receive royalties when TWi makes — and Anchen Pharmaceuticals Inc. and Anchen Inc. sell — generic Intuniv tablets in all dosages effective July 1, 2016. Anchen, a Par subsidiary, is TWi’s authorized distributor, but is also authorized under the...
To view the full article, register now.